View Financial HealthEssbio 배당 및 자사주 매입배당 기준 점검 3/6Essbio 수익으로 충분히 충당되는 현재 수익률 2.95% 보유한 배당금 지급 회사입니다. 다음 지급일은 28th May, 2026 이며 배당락일은 다음과 같습니다. 25th May, 2026.핵심 정보2.9%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률-10.3%다음 배당 지급일28 May 26배당락일25 May 26주당 배당금n/a배당 성향27%최근 배당 및 자사주 매입 업데이트Declared Dividend • Mar 25Dividend increased to CL$0.37Dividend of CL$0.37 is 27% higher than last year. Ex-date: 25th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 9.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 24Essbio S.A. announces Annual dividend, payable on May 28, 2026Essbio S.A. announced Annual dividend of CLP 0.3749 per share payable on May 28, 2026, ex-date on May 25, 2026 and record date on May 22, 2026.분석 기사 • Mar 27Essbio's (SNSE:ESSBIO-C) Dividend Will Be Reduced To CLP0.2943Essbio S.A. ( SNSE:ESSBIO-C ) is reducing its dividend from last year's comparable payment to CLP0.2943 on the 23rd of...Declared Dividend • Mar 27Dividend of CL$0.29 announcedShareholders will receive a dividend of CL$0.29. Ex-date: 19th May 2025 Payment date: 23rd May 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 26Essbio S.A. announces Annual dividend, payable on May 23, 2025Essbio S.A. announced Annual dividend of CLP 0.2943 per share payable on May 23, 2025, ex-date on May 19, 2025 and record date on May 16, 2025.Upcoming Dividend • May 10Upcoming dividend of CL$1.13 per shareEligible shareholders must have bought the stock before 17 May 2024. Payment date: 23 May 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 9.0%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.4%).모든 업데이트 보기Recent updatesBoard Change • May 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Declared Dividend • Mar 25Dividend increased to CL$0.37Dividend of CL$0.37 is 27% higher than last year. Ex-date: 25th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 9.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 25Full year 2025 earnings released: EPS: CL$0.001 (vs CL$0.98 in FY 2024)Full year 2025 results: EPS: CL$0.001. Revenue: CL$261.5b (up 7.4% from FY 2024). Net income: CL$33.0b (up 27% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue.공시 • Mar 24Essbio S.A. announces Annual dividend, payable on May 28, 2026Essbio S.A. announced Annual dividend of CLP 0.3749 per share payable on May 28, 2026, ex-date on May 25, 2026 and record date on May 22, 2026.Valuation Update With 7 Day Price Move • Dec 17Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to CL$9.99, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 13x in the Water Utilities industry in South America. Total returns to shareholders of 5.8% over the past three years.분석 기사 • Dec 16Essbio (SNSE:ESSBIO-C) Shareholders Will Want The ROCE Trajectory To ContinueIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...New Risk • Dec 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Board Change • Dec 09No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Oct 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Sep 14Second quarter 2025 earnings released: EPS: CL$0.16 (vs CL$0.13 in 2Q 2024)Second quarter 2025 results: EPS: CL$0.16 (up from CL$0.13 in 2Q 2024). Revenue: CL$60.9b (up 6.8% from 2Q 2024). Net income: CL$4.20b (up 26% from 2Q 2024). Profit margin: 6.9% (up from 5.8% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.분석 기사 • Sep 04Is Essbio (SNSE:ESSBIO-C) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Sep 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.분석 기사 • Mar 27Essbio's (SNSE:ESSBIO-C) Dividend Will Be Reduced To CLP0.2943Essbio S.A. ( SNSE:ESSBIO-C ) is reducing its dividend from last year's comparable payment to CLP0.2943 on the 23rd of...Declared Dividend • Mar 27Dividend of CL$0.29 announcedShareholders will receive a dividend of CL$0.29. Ex-date: 19th May 2025 Payment date: 23rd May 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 26Essbio S.A. announces Annual dividend, payable on May 23, 2025Essbio S.A. announced Annual dividend of CLP 0.2943 per share payable on May 23, 2025, ex-date on May 19, 2025 and record date on May 16, 2025.공시 • Mar 25Essbio S.A., Annual General Meeting, Apr 24, 2025Essbio S.A., Annual General Meeting, Apr 24, 2025. Location: av arturo prat 199, torre b 15th floor, concepcion ChileBoard Change • Jan 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Dec 24No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: CL$176.1b (up 234% from 3Q 2023). Net income: CL$22.9b (up 304% from 3Q 2023). Profit margin: 13% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue.Reported Earnings • Sep 13Second quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.22 in 2Q 2023)Second quarter 2024 results: EPS: CL$1.00. Revenue: CL$57.6b (up 1.9% from 2Q 2023). Net income: CL$3.33b (down 43% from 2Q 2023). Profit margin: 5.8% (down from 10% in 2Q 2023). The decrease in margin was driven by higher expenses.New Risk • Jun 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.분석 기사 • May 21Investors Appear Satisfied With Essbio S.A.'s (SNSE:ESSBIO-C) Prospects As Shares Rocket 48%Essbio S.A. ( SNSE:ESSBIO-C ) shareholders have had their patience rewarded with a 48% share price jump in the last...Reported Earnings • May 19First quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.43 in 1Q 2023)First quarter 2024 results: EPS: CL$1.00 (up from CL$0.43 in 1Q 2023). Revenue: CL$69.2b (up 5.2% from 1Q 2023). Net income: CL$14.0b (up 22% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 17Investor sentiment improves as stock rises 48%After last week's 48% share price gain to CL$14.70, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 12x in the Water Utilities industry in South America. Total returns to shareholders of 59% over the past three years.Upcoming Dividend • May 10Upcoming dividend of CL$1.13 per shareEligible shareholders must have bought the stock before 17 May 2024. Payment date: 23 May 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 9.0%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.4%).Reported Earnings • Mar 17Full year 2023 earnings released: EPS: CL$2.00 (vs CL$0.27 in FY 2022)Full year 2023 results: EPS: CL$2.00 (up from CL$0.27 in FY 2022). Revenue: CL$235.2b (up 7.5% from FY 2022). Net income: CL$29.7b (up 315% from FY 2022). Profit margin: 13% (up from 3.3% in FY 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Upcoming Dividend • Dec 11Upcoming dividend of CL$0.45 per share at 8.9% yieldEligible shareholders must have bought the stock before 18 December 2023. Payment date: 21 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 8.9%. Lower than top quartile of Chilean dividend payers (12%). Higher than average of industry peers (3.0%).Reported Earnings • Aug 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: CL$56.8b (up 14% from 2Q 2022). Net income: CL$5.79b (up CL$8.71b from 2Q 2022). Profit margin: 10% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Apr 17Upcoming dividend of CL$0.27 per share at 2.3% yieldEligible shareholders must have bought the stock before 24 April 2023. Payment date: 28 April 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.3%. Lower than top quartile of Chilean dividend payers (13%). Lower than average of industry peers (3.9%).Reported Earnings • Nov 25Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CL$49.1b (up 14% from 3Q 2021). Net loss: CL$4.22b (down 228% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Board Change • Nov 16No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.분석 기사 • Sep 15We Think That There Are More Issues For Essbio (SNSE:ESSBIO-C) Than Just Sluggish EarningsEssbio S.A.'s ( SNSE:ESSBIO-C ) recent weak earnings report didn't cause a big stock movement. However, we believe that...Reported Earnings • Sep 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CL$49.9b (up 15% from 2Q 2021). Net loss: CL$2.92b (down 201% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.Reported Earnings • May 15First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: CL$59.7b (up 17% from 1Q 2021). Net income: CL$11.7b (up 18% from 1Q 2021). Profit margin: 20% (in line with 1Q 2021).Upcoming Dividend • May 13Upcoming dividend of CL$0.70 per shareEligible shareholders must have bought the stock before 20 May 2022. Payment date: 26 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.9%. Lower than top quartile of Chilean dividend payers (11%). Higher than average of industry peers (3.7%).Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Mar 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: CL$189.8b (up 9.2% from FY 2020). Net income: CL$18.5b (down 11% from FY 2020). Profit margin: 9.7% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Dec 04Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: CL$43.4b (up 14% from 3Q 2020). Net income: CL$3.31b (up 54% from 3Q 2020). Profit margin: 7.6% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.Reported Earnings • Sep 12Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CL$43.5b (up 8.0% from 2Q 2020). Net income: CL$2.88b (down 24% from 2Q 2020). Profit margin: 6.6% (down from 9.5% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.분석 기사 • May 30Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 20First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CL$51.3b (up 4.1% from 1Q 2020). Net income: CL$9.87b (down 6.3% from 1Q 2020). Profit margin: 19% (down from 21% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 07Upcoming dividend of CL$0.24 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 19 May 2021. Trailing yield: 3.9%. Lower than top quartile of Chilean dividend payers (6.1%). Higher than average of industry peers (3.1%).분석 기사 • Mar 29A Look At The Intrinsic Value Of Essbio S.A. (SNSE:ESSBIO-C)How far off is Essbio S.A. ( SNSE:ESSBIO-C ) from its intrinsic value? Using the most recent financial data, we'll take...Reported Earnings • Mar 29Full year 2020 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CL$174.4b (up 3.1% from FY 2019). Net income: CL$20.8b (up 1.4% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 7% per year.분석 기사 • Mar 09Should You Be Impressed By Essbio's (SNSE:ESSBIO-C) Returns on Capital?If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...분석 기사 • Feb 15Here's Why Essbio (SNSE:ESSBIO-C) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 04Should Essbio S.A. (SNSE:ESSBIO-C) Focus On Improving This Fundamental Metric?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...분석 기사 • Dec 08Has Essbio (SNSE:ESSBIO-C) Got What It Takes To Become A Multi-Bagger?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...분석 기사 • Nov 17Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...예정된 배당 지급오늘May 22 2026배당락일May 25 2026배당 지급일May 28 20263 days (배당락일 기준)다음 배당금을 받으려면 앞으로 3 days일 이내에 매수하세요지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: ESSBIO-C 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: ESSBIO-C 의 배당금 지급액은 지난 10 년 동안 감소했습니다.배당 수익률 vs 시장Essbio 배당 수익률 vs 시장ESSBIO-C의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ESSBIO-C)2.9%시장 하위 25% (CL)2.2%시장 상위 25% (CL)6.5%업계 평균 (Water Utilities)3.0%분석가 예측 (ESSBIO-C) (최대 3년)n/a주목할만한 배당금: ESSBIO-C 의 배당금( 2.95% )은 CL 시장에서 배당금 지급자의 하위 25%( 2.25% )보다 높습니다.고배당: ESSBIO-C 의 배당금( 2.95% )은 CL 시장에서 배당금 지급자의 상위 25%( 6.53% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 27.5% )로 ESSBIO-C 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 23.9% )이 낮기 때문에 ESSBIO-C 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCL 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 10:57종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Essbio S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Declared Dividend • Mar 25Dividend increased to CL$0.37Dividend of CL$0.37 is 27% higher than last year. Ex-date: 25th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 9.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 24Essbio S.A. announces Annual dividend, payable on May 28, 2026Essbio S.A. announced Annual dividend of CLP 0.3749 per share payable on May 28, 2026, ex-date on May 25, 2026 and record date on May 22, 2026.
분석 기사 • Mar 27Essbio's (SNSE:ESSBIO-C) Dividend Will Be Reduced To CLP0.2943Essbio S.A. ( SNSE:ESSBIO-C ) is reducing its dividend from last year's comparable payment to CLP0.2943 on the 23rd of...
Declared Dividend • Mar 27Dividend of CL$0.29 announcedShareholders will receive a dividend of CL$0.29. Ex-date: 19th May 2025 Payment date: 23rd May 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 26Essbio S.A. announces Annual dividend, payable on May 23, 2025Essbio S.A. announced Annual dividend of CLP 0.2943 per share payable on May 23, 2025, ex-date on May 19, 2025 and record date on May 16, 2025.
Upcoming Dividend • May 10Upcoming dividend of CL$1.13 per shareEligible shareholders must have bought the stock before 17 May 2024. Payment date: 23 May 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 9.0%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.4%).
Board Change • May 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Declared Dividend • Mar 25Dividend increased to CL$0.37Dividend of CL$0.37 is 27% higher than last year. Ex-date: 25th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 9.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 25Full year 2025 earnings released: EPS: CL$0.001 (vs CL$0.98 in FY 2024)Full year 2025 results: EPS: CL$0.001. Revenue: CL$261.5b (up 7.4% from FY 2024). Net income: CL$33.0b (up 27% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue.
공시 • Mar 24Essbio S.A. announces Annual dividend, payable on May 28, 2026Essbio S.A. announced Annual dividend of CLP 0.3749 per share payable on May 28, 2026, ex-date on May 25, 2026 and record date on May 22, 2026.
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to CL$9.99, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 13x in the Water Utilities industry in South America. Total returns to shareholders of 5.8% over the past three years.
분석 기사 • Dec 16Essbio (SNSE:ESSBIO-C) Shareholders Will Want The ROCE Trajectory To ContinueIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
New Risk • Dec 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Board Change • Dec 09No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Oct 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 14Second quarter 2025 earnings released: EPS: CL$0.16 (vs CL$0.13 in 2Q 2024)Second quarter 2025 results: EPS: CL$0.16 (up from CL$0.13 in 2Q 2024). Revenue: CL$60.9b (up 6.8% from 2Q 2024). Net income: CL$4.20b (up 26% from 2Q 2024). Profit margin: 6.9% (up from 5.8% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
분석 기사 • Sep 04Is Essbio (SNSE:ESSBIO-C) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Sep 03No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
분석 기사 • Mar 27Essbio's (SNSE:ESSBIO-C) Dividend Will Be Reduced To CLP0.2943Essbio S.A. ( SNSE:ESSBIO-C ) is reducing its dividend from last year's comparable payment to CLP0.2943 on the 23rd of...
Declared Dividend • Mar 27Dividend of CL$0.29 announcedShareholders will receive a dividend of CL$0.29. Ex-date: 19th May 2025 Payment date: 23rd May 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 4.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 26Essbio S.A. announces Annual dividend, payable on May 23, 2025Essbio S.A. announced Annual dividend of CLP 0.2943 per share payable on May 23, 2025, ex-date on May 19, 2025 and record date on May 16, 2025.
공시 • Mar 25Essbio S.A., Annual General Meeting, Apr 24, 2025Essbio S.A., Annual General Meeting, Apr 24, 2025. Location: av arturo prat 199, torre b 15th floor, concepcion Chile
Board Change • Jan 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Dec 24No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (9 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: CL$176.1b (up 234% from 3Q 2023). Net income: CL$22.9b (up 304% from 3Q 2023). Profit margin: 13% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue.
Reported Earnings • Sep 13Second quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.22 in 2Q 2023)Second quarter 2024 results: EPS: CL$1.00. Revenue: CL$57.6b (up 1.9% from 2Q 2023). Net income: CL$3.33b (down 43% from 2Q 2023). Profit margin: 5.8% (down from 10% in 2Q 2023). The decrease in margin was driven by higher expenses.
New Risk • Jun 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
분석 기사 • May 21Investors Appear Satisfied With Essbio S.A.'s (SNSE:ESSBIO-C) Prospects As Shares Rocket 48%Essbio S.A. ( SNSE:ESSBIO-C ) shareholders have had their patience rewarded with a 48% share price jump in the last...
Reported Earnings • May 19First quarter 2024 earnings released: EPS: CL$1.00 (vs CL$0.43 in 1Q 2023)First quarter 2024 results: EPS: CL$1.00 (up from CL$0.43 in 1Q 2023). Revenue: CL$69.2b (up 5.2% from 1Q 2023). Net income: CL$14.0b (up 22% from 1Q 2023). Profit margin: 20% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 17Investor sentiment improves as stock rises 48%After last week's 48% share price gain to CL$14.70, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 12x in the Water Utilities industry in South America. Total returns to shareholders of 59% over the past three years.
Upcoming Dividend • May 10Upcoming dividend of CL$1.13 per shareEligible shareholders must have bought the stock before 17 May 2024. Payment date: 23 May 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 9.0%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.4%).
Reported Earnings • Mar 17Full year 2023 earnings released: EPS: CL$2.00 (vs CL$0.27 in FY 2022)Full year 2023 results: EPS: CL$2.00 (up from CL$0.27 in FY 2022). Revenue: CL$235.2b (up 7.5% from FY 2022). Net income: CL$29.7b (up 315% from FY 2022). Profit margin: 13% (up from 3.3% in FY 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 11Upcoming dividend of CL$0.45 per share at 8.9% yieldEligible shareholders must have bought the stock before 18 December 2023. Payment date: 21 December 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 8.9%. Lower than top quartile of Chilean dividend payers (12%). Higher than average of industry peers (3.0%).
Reported Earnings • Aug 27Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: CL$56.8b (up 14% from 2Q 2022). Net income: CL$5.79b (up CL$8.71b from 2Q 2022). Profit margin: 10% (up from net loss in 2Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Apr 17Upcoming dividend of CL$0.27 per share at 2.3% yieldEligible shareholders must have bought the stock before 24 April 2023. Payment date: 28 April 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.3%. Lower than top quartile of Chilean dividend payers (13%). Lower than average of industry peers (3.9%).
Reported Earnings • Nov 25Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CL$49.1b (up 14% from 3Q 2021). Net loss: CL$4.22b (down 228% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Board Change • Nov 16No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
분석 기사 • Sep 15We Think That There Are More Issues For Essbio (SNSE:ESSBIO-C) Than Just Sluggish EarningsEssbio S.A.'s ( SNSE:ESSBIO-C ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Reported Earnings • Sep 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CL$49.9b (up 15% from 2Q 2021). Net loss: CL$2.92b (down 201% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.
Reported Earnings • May 15First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: CL$59.7b (up 17% from 1Q 2021). Net income: CL$11.7b (up 18% from 1Q 2021). Profit margin: 20% (in line with 1Q 2021).
Upcoming Dividend • May 13Upcoming dividend of CL$0.70 per shareEligible shareholders must have bought the stock before 20 May 2022. Payment date: 26 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.9%. Lower than top quartile of Chilean dividend payers (11%). Higher than average of industry peers (3.7%).
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Director Olga Botero Pelaez was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 12Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: CL$189.8b (up 9.2% from FY 2020). Net income: CL$18.5b (down 11% from FY 2020). Profit margin: 9.7% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Dec 04Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: CL$43.4b (up 14% from 3Q 2020). Net income: CL$3.31b (up 54% from 3Q 2020). Profit margin: 7.6% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.
Reported Earnings • Sep 12Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CL$43.5b (up 8.0% from 2Q 2020). Net income: CL$2.88b (down 24% from 2Q 2020). Profit margin: 6.6% (down from 9.5% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
분석 기사 • May 30Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 20First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CL$51.3b (up 4.1% from 1Q 2020). Net income: CL$9.87b (down 6.3% from 1Q 2020). Profit margin: 19% (down from 21% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 07Upcoming dividend of CL$0.24 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 19 May 2021. Trailing yield: 3.9%. Lower than top quartile of Chilean dividend payers (6.1%). Higher than average of industry peers (3.1%).
분석 기사 • Mar 29A Look At The Intrinsic Value Of Essbio S.A. (SNSE:ESSBIO-C)How far off is Essbio S.A. ( SNSE:ESSBIO-C ) from its intrinsic value? Using the most recent financial data, we'll take...
Reported Earnings • Mar 29Full year 2020 earnings releasedThe company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CL$174.4b (up 3.1% from FY 2019). Net income: CL$20.8b (up 1.4% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 7% per year.
분석 기사 • Mar 09Should You Be Impressed By Essbio's (SNSE:ESSBIO-C) Returns on Capital?If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
분석 기사 • Feb 15Here's Why Essbio (SNSE:ESSBIO-C) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jan 04Should Essbio S.A. (SNSE:ESSBIO-C) Focus On Improving This Fundamental Metric?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
분석 기사 • Dec 08Has Essbio (SNSE:ESSBIO-C) Got What It Takes To Become A Multi-Bagger?What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...
분석 기사 • Nov 17Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...